1980 Results
Sort By:
Published on October 14, 2015
The HudsonAlpha Institute for Biotechnology said today it has won a $100,000 grant from the Jane K. Lowe Charitable Foundation to help establish a clinical genomics program. The foundation said the $100,000 will provide funds to support five new HudsonAlpha faculty members “who will work with existing faculty to bring scalable, cost…
Published on October 6, 2015
When Lorraine Potocki, M.D., attended medical school in the 1980s she didn’t have exposure to a genetics class. Dr. Potocki, a professor at Houston, TX-based Baylor College of Medicine’s department of Molecular and Human Genetics, wasn’t even aware that there were training programs in genetics until her residency was well…
Published on October 2, 2015
Genomic medicine is already demonstrating its valuable uses in pediatric oncology. These uses, however, are mainly limited to diagnostics and risk stratification. Another use, perhaps the most ambitious use, is the development of personalized treatment plans. However, whether or not treatment plans for individual patients can be customized on the…
Published on October 1, 2015
When people talk about the $1,000 genome, they are not speaking about the whole genome, but the exons, the so-called coding regions of the genome. “Six years ago, I was spending $15,000 per exome sequence,” says Gholson Lyon, M.D., Ph.D., a genomic scientist working for the Cold Spring Harbor Laboratory.…
Published on October 1, 2015
Amoy Diagnostics and Illumina are embarking on a collaboration to speed up the adoption of precision medicine and targeted therapies in China. Amoy will develop and commercialize a series of oncology-related tests based on Illumina's next-generation sequencing (NGS) platforms, including the recently released research-use-only TruSight Tumor 15 as transferred from…
Published on September 30, 2015
Scientists at the University of Washington School of Medicine in St. Louis have devised a new metagenomics shotgun sequencing approach that they believe has the capacity to detect virtually any virus that infects people or animals. Thousands of different viruses are known to cause illness, but making a diagnosis can…
Published on September 22, 2015
Working with tissue, blood, and DNA from six people with precancerous and cancerous lung lesions, scientists from Johns Hopkins scientists say they have identified what they believe are among the very earliest premalignant genetic changes that mark the potential onset of the most common and deadliest form of disease. In…
Published on September 9, 2015
Asuragen agreed to collaborate with Illumina to set up a framework for the development and commercialization of sequencing-based companion diagnostics in partnership with biotech and pharmaceutical companies. Asuragen officials say they will leverage its Quantidex™ NGS product platform for development of customized companion diagnostics for its biotech and pharma partners…
Published on September 1, 2015
Paradigm and TME Research launched the Paradigm Neoadjuvant Breast Registry. The system will use Paradigm’s PCDx next-generation sequencing test and other advanced molecular capabilities to genomically characterize invasive breast cancer patients for targeted neoadjuvant therapies [presurgical treatment]. With more accurate accounts of individual gene variability driving disease, therapy selection will be…
Published on August 27, 2015
Conducted repeatedly, a blood test capable of profiling circulating tumor DNA can track genetic changes that occur over time, picking up signs that a treated cancer—in this case, breast cancer—is about to return. The blood test, a so-called liquid biopsy, detects mutations in DNA shed by cancer cells, and it…
Published on August 26, 2015
While the incidence of acute myeloid leukemia (AML) is still relatively rare, accounting for approximately 1% of cancer deaths in the U.S., rates of occurrence are expected to rise as the largest portion of the population continues to age. Moreover, there remains a significant level of disparity in clinical outcomes,…
Published on August 25, 2015
Illumina and Burning Rock said today they will collaborate to develop new clinical molecular diagnostics aimed at cancer. The value of the partnership was not disclosed. Under the collaboration, Burning Rock will develop advanced clinical applications for molecular diagnostics in oncology based on Illumina's next-generation sequencing (NGS) technology. Specifically, the…
Published on August 18, 2015
Illumina, Warburg Pincus, and Sutter Hill Ventures set up a company with the goal of helping consumers discover insights into their own genomes. The new firm, Helix, is based in the San Francisco Bay Area and reported received financing commitments in excess of $100 million. “Genomics is reaching an inflection…
Published on August 18, 2015
Biogen, the ALS Association, and Columbia University Medical Center (CUMC) agreed to collaborate to better understand the differences and commonalities in the ALS disease process and how genes influence the clinical features of the disease. The project, “Genomic Translation for ALS Clinical care” (GTAC), will involve a combination of next-generation…
Published on August 10, 2015
Illumina said today it will acquire GenoLogics Life Sciences Software, a developer of laboratory information management systems (LIMS) for life science organizations, in a deal intended to strengthen the buyer’s portfolio of genetic analysis solutions. The price was not disclosed. GenoLogics’ Clarity LIMS™ software, adopted by more than 120 genomic…